Bremelanotide

Investigated uses

• Hypoactive sexual desire disorder and earlier sexual-function research.

Mechanism and hypotheses

• Bremelanotide is a melanocortin-receptor agonist; the exact pathway by which the approved product improves hypoactive sexual desire disorder is not fully established.
• Hypothesized: Effects promoted for men, performance or other nonlabeled goals are not established by the approved indication.

Human evidence

• Two pivotal randomized trials supported Vyleesi approval for acquired generalized HSDD in premenopausal women. Limitations: Narrow indication and prefilled formulation; does not establish gray PT-141 vial equivalence.

Safety highlights

• Nausea, flushing, injection-site reactions, headache and vomiting are common labeled adverse reactions.
• Transient blood-pressure increases and heart-rate reductions can occur; focal hyperpigmentation may be persistent.

Regulatory context

Vyleesi is FDA-approved as a prefilled autoinjector for a narrow indication; gray PT-141 powder is not that product.